



Mylan to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

September 9, 2020

HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company [Mylan N.V.](#) (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury, together with President Rajiv Malik will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Wednesday, Sep. 16, 2020, at 4:15 p.m. ET. Upjohn's Group President Michael Goettler and Upjohn's Chief Financial Officer Sanjeev Narula will also be in attendance. Coury, Goettler, Malik and Narula will serve as future executive chairman, chief executive officer, president and chief financial officer of Viatrix, respectively.

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's website at [investor.mylan.com](#). An archived version also will be available following the live presentation and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at [Mylan.com](#). We routinely post information that may be important to investors on our website at [investor.mylan.com](#)

Forward-Looking Statements

This communication contains "forward-looking statements", including statements about completing the proposed combination of Upjohn Inc. ("Upjohn") and Mylan N.V. ("Mylan"), which will immediately follow the proposed separation of the Upjohn business (the "Upjohn Business") from Pfizer Inc. ("Pfizer") (the "proposed transaction"). Forward looking statements may often be identified by the use of words such as "will", "may", "could", "should", "would", "project", "believe", "anticipate", "expect", "plan", "estimate", "potential", "intend", "continue", "target", "seek" and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: ongoing challenges and uncertainties posed by the COVID-19 pandemic for businesses and governments around the world; the parties' ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; the parties' ability to consummate the proposed transaction; the conditions to the completion of the proposed transaction not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at all; and uncertainties and matters beyond the control of management and other factors described under "Risk Factors" in each of Pfizer's, Upjohn's and Mylan's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission ("SEC"). These risks, as well as other risks associated with Mylan, the Upjohn Business, the combined company and the proposed transaction are also more fully discussed in the Registration Statement on Form S-4, as amended, which includes a proxy statement/prospectus (as amended, the "Form S-4"), which was filed by Upjohn with the SEC on October 25, 2019 and declared effective by the SEC on February 13, 2020, the Registration Statement on Form 10, which includes an information statement (the "Form 10"), which was filed by Upjohn with the SEC on June 12, 2020 and declared effective by the SEC on June 30, 2020, a final information statement furnished with the Current Report on Form 8-K filed by Upjohn with the SEC on August 6, 2020 (the "Final Information Statement"), a definitive proxy statement, which was filed by Mylan with the SEC on February 13, 2020 (the "Proxy Statement"), and a prospectus, which was filed by Upjohn with the SEC on February 13, 2020 (the "Prospectus"). You can access Pfizer's, Mylan's and Upjohn's filings with the SEC through the SEC website at [www.sec.gov](#) or through Pfizer's or Mylan's website, as applicable, and Pfizer and Mylan strongly encourage you to do so. Except as required by applicable law, Pfizer, Mylan and Upjohn undertake no obligation to update any statements herein for revisions or changes after this communication is made.

Additional Information and Where to Find It

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. In connection with the proposed transaction, Upjohn and Mylan have filed certain materials with the SEC, including, among other materials, the Form S-4, Form 10 and Prospectus filed by Upjohn and the Proxy Statement filed by Mylan. The Form S-4 was declared effective on February 13, 2020 and the Proxy Statement and the Prospectus were first mailed to shareholders of Mylan on or about February 14, 2020 to seek approval of the proposed transaction. The Form 10 was declared effective on June 30, 2020. The Final Information Statement was made available to Pfizer stockholders on or about August 6, 2020. Upjohn and Mylan intend to file additional relevant materials with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, UPJOHN AND THE PROPOSED TRANSACTION. The documents relating to the proposed transaction (when they are available) can be obtained free of charge from the SEC's website at [www.sec.gov](#). These documents (when they are available) can also be obtained free of charge from Mylan, upon written request to Mylan or by contacting Mylan at (724) 514-1813 or [investor_relations@mylan.com](#) or from Pfizer on Pfizer's internet website at [https://investors.Pfizer.com/financials/sec-filings/default.aspx](#) or by contacting Pfizer's Investor Relations Department at (212) 733-2323, as applicable.



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/mylan-to-present-at-the-morgan-stanley-virtual-18th-annual-global-healthcare-conference-301126729.html>

SOURCE Mylan N.V.

Christine Waller (Media), 724.514.1968, Melissa Trombetta (Investors), 724.514.1813